Condition
Mesothelioma
Estimated Enrollment: 19
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 2005-0288|NCI-2012-01381
Study First Received: November 20, 2006
Last Updated: November 16, 2015
Estimated Primary Completion Date: February 2014
Primary Outcome Measures:
Maximum Tolerated Dose (MTD) of Cisplatin, Pemetrexed, and Imatinib Mesylate Given to Participants with Unresectable or Metastatic Malignant Mesothelioma
Sponsors and Collaborators:
M.D. Anderson Cancer Center|Novartis
Website Link: https://ClinicalTrials.gov/show/NCT00402766
